Literature DB >> 20865289

The HPV-16 E7 oncoprotein is expressed mainly from the unspliced E6/E7 transcript in cervical carcinoma C33-A cells.

Oscar del Moral-Hernández1, Eduardo López-Urrutia, Raúl Bonilla-Moreno, Martha Martínez-Salazar, Elena Arechaga-Ocampo, Jaime Berumen, Nicolás Villegas-Sepúlveda.   

Abstract

The HPV-16 E6/E7 early transcripts are first produced as bicistronic or polycistronic mRNAs, and about 90% of the original pre-mRNA is spliced to produce three new alternative mRNAs. HPV-16 spliced transcripts are expressed heterogeneously in tumors and cell lines. Our results suggest that suboptimal splicing acceptor sites in E6/E7 intron 1 and the differential expression of splicing factors are involved in the production of the heterogeneous splicing profile in cell lines. The unspliced pre-mRNA and the alternative spliced transcripts contribute differentially to the production of E7 in stably transfected C33-A cells. The highest level of E7 was produced from the least prevalent transcript, the unspliced E6/E7(pre-mRNA). The order of relative expression of E7 was unspliced E6/E7(pre-mRNA) > E6*I/E7 > E6*II/E7. Our findings suggest that E6/E7 alternative splicing may be a mechanism for differential expression of the E6 and E7 oncoproteins, which also affects the expression of their targets, the proteins p53 and pRb.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865289     DOI: 10.1007/s00705-010-0787-9

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  9 in total

1.  Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.

Authors:  Denise M Schütze; Peter J F Snijders; Leontien Bosch; Duco Kramer; Chris J L M Meijer; Renske D M Steenbergen
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

2.  P16INK4A is required for cisplatin resistance in cervical carcinoma SiHa cells.

Authors:  Yueran Li; Songshu Xiao; Liu Dan; Min Xue
Journal:  Oncol Lett       Date:  2014-12-19       Impact factor: 2.967

3.  Comparative RNA sequencing reveals that HPV16 E6 abrogates the effect of E6*I on ROS metabolism.

Authors:  Philippe Paget-Bailly; Koceila Meznad; Diane Bruyère; Jérôme Perrard; Michael Herfs; Alain C Jung; Christiane Mougin; Jean-Luc Prétet; Aurélie Baguet
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

4.  A unique insert in the genomes of high-risk human papillomaviruses with a predicted dual role in conferring oncogenic risk.

Authors:  Noam Auslander; Yuri I Wolf; Svetlana A Shabalina; Eugene V Koonin
Journal:  F1000Res       Date:  2019-07-02

5.  E6/E7 Variants of Human Papillomavirus 16 Associated with Cervical Carcinoma in Women in Southern Mexico.

Authors:  Ramón Antaño-Arias; Oscar Del Moral-Hernández; Julio Ortiz-Ortiz; Luz Del Carmen Alarcón-Romero; Jorge Adán Navor-Hernández; Marco Antonio Leyva-Vázquez; Marco Antonio Jiménez-López; Jorge Organista-Nava; Berenice Illades-Aguiar
Journal:  Pathogens       Date:  2021-06-20

6.  Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes.

Authors:  Lin Lin; Qingqing Cai; Xiaoyan Zhang; Hongwei Zhang; Yang Zhong; Congjian Xu; Yanyun Li
Journal:  Protein Cell       Date:  2015-04-28       Impact factor: 14.870

7.  miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ.

Authors:  Hyun Min Jung; Brittany L Phillips; Edward Kl Chan
Journal:  Mol Cancer       Date:  2014-04-08       Impact factor: 27.401

Review 8.  The Role of E6 Spliced Isoforms (E6*) in Human Papillomavirus-Induced Carcinogenesis.

Authors:  Leslie Olmedo-Nieva; J Omar Muñoz-Bello; Adriana Contreras-Paredes; Marcela Lizano
Journal:  Viruses       Date:  2018-01-18       Impact factor: 5.048

9.  Heterogeneous Nuclear Ribonucleoprotein A1 (hnRNP A1) and hnRNP A2 Inhibit Splicing to Human Papillomavirus 16 Splice Site SA409 through a UAG-Containing Sequence in the E7 Coding Region.

Authors:  Yunji Zheng; Johanna Jönsson; Chengyu Hao; Shirin Shoja Chaghervand; Xiaoxu Cui; Naoko Kajitani; Lijing Gong; Chengjun Wu; Stefan Schwartz
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.